Mutant V600E BRAF Increases Hypoxia Inducible Factor-1α Expression in Melanoma

Mutations in the BRAF serine/threonine kinase gene are frequently found in cutaneous melanomas. Activation of hypoxia inducible factor-1alpha (HIF-1alpha) in response to both hypoxic stress and oncogenic signals has important implications in cancer development and progression. Here, we report that mutant BRAF(V600E) increases HIF-1alpha expression in melanoma cells. Our microarray profiling data in 35 melanoma and melanocyte cell lines showed that HIF-1alpha gene expression was significantly increased in melanomas harboring BRAF(V600E) mutation. Stable suppression of mutant BRAF(V600E) or both wild-type and mutant BRAF(V600E) by RNA interference in melanoma cells resulted in significantly decreased HIF-1alpha expression. Knockdown of mutant BRAF(V600E) induced significant reduction of cell survival and proliferation under hypoxic conditions, whereas knockdown of both wild-type and mutant BRAF(V600E) resulted in further reduction. The effects of BRAF knockdown can be rescued by reintroducing BRAF(V600E) into tumor cells. Transfection of BRAF(V600E) into melanoma cells with wild-type BRAF induced significantly more hypoxic tolerance. Knockdown of HIF-1alpha in melanoma cells resulted in decreased cell survival under hypoxic conditions. Pharmacologic inhibition of BRAF by BAY 43-9006 also resulted in decreased HIF-1alpha expression. Although HIF-1alpha translational rate was not changed, the protein was less stable in BRAF knockdown cells. In additional, von Hippel-Lindau protein expression was significantly increased in BRAF knockdown cells. Our data show for the first time that BRAF(V600E) mutation increases HIF-1alpha expression and melanoma cell survival under hypoxic conditions and suggest that effects of the oncogenic V600E BRAF mutation may be partially mediated through the HIF-1alpha pathway.

[1]  N. Ibrahim,et al.  Therapeutic targets in melanoma: MAPKinase pathway , 2006, Current oncology reports.

[2]  Jung Hun Song,et al.  Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. , 2006, The Journal of clinical endocrinology and metabolism.

[3]  Xiaowei Xu,et al.  Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells , 2006, Melanoma research.

[4]  V. Trovisco,et al.  B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. , 2006, Human pathology.

[5]  F. Lozupone,et al.  Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma , 2006, Oncogene.

[6]  Joseph A Garcia,et al.  HIFing the Brakes: Therapeutic Opportunities for Treatment of Human Malignancies , 2006, Science's STKE.

[7]  N. Thomas BRAF somatic mutations in malignant melanoma and melanocytic naevi , 2006, Melanoma research.

[8]  Paul A. Khavari,et al.  Modelling cancer in human skin tissue , 2006, Nature Reviews Cancer.

[9]  M. Baccarini,et al.  Essential role of B-Raf in ERK activation during extraembryonic development , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. Fukushima,et al.  Roles of RAS and BRAF mutations in thyroid carcinogenesis. , 2005, Fukushima journal of medical science.

[11]  G. Soff,et al.  Update on angiogenesis inhibitors. , 2005, Current opinion in oncology.

[12]  M. Piepkorn The Spitz nevus is melanoma. , 2005, The American Journal of dermatopathology.

[13]  D. Aust,et al.  Mutations of the BRAF gene in ulcerative colitis‐related colorectal carcinoma , 2005 .

[14]  A. Harris,et al.  HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression , 2005 .

[15]  D. Tuveson,et al.  Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.

[16]  D. Elder,et al.  Functional erythropoietin autocrine loop in melanoma. , 2005, The American journal of pathology.

[17]  L. Bingle,et al.  In vitro study of HIF‐1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI‐3K/Akt and MEK1/ERK pathways , 2005, The Journal of pathology.

[18]  Mi-Ock Lee,et al.  Novel Function of Orphan Nuclear Receptor Nur77 in Stabilizing Hypoxia-inducible Factor-1α* , 2004, Journal of Biological Chemistry.

[19]  Jung Weon Lee,et al.  Ras-dependent induction of HIF-1α785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion , 2004, Oncogene.

[20]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[21]  D. Morton,et al.  Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas , 2004, Clinical Cancer Research.

[22]  L. Huang,et al.  Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform: implications for tumor promotion. , 2003, Cancer research.

[23]  G. Powis,et al.  Hypoxia inducible factor as a cancer drug target. , 2003, Current cancer drug targets.

[24]  D. Tuveson,et al.  Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.

[25]  C. Pritchard,et al.  Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.

[26]  J. McCubrey,et al.  BAY-43-9006 Bayer/Onyx. , 2003, Current opinion in investigational drugs.

[27]  Manfred Kunz,et al.  Molecular responses to hypoxia in tumor cells , 2003, Molecular Cancer.

[28]  D. Elder,et al.  Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. , 2003, Cancer research.

[29]  P. Ratcliffe,et al.  The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. , 2003, Seminars in cancer biology.

[30]  P. Maxwell Oxygen homeostasis and cancer: insights from a rare disease. , 2002, Clinical medicine.

[31]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[32]  C. Peyssonnaux,et al.  The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.

[33]  L. Poellinger,et al.  Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor protein , 2000, The EMBO journal.

[34]  U. Rapp,et al.  Isotype-specific functions of Raf kinases. , 1999, Experimental cell research.

[35]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[36]  U. Rapp,et al.  Endothelial apoptosis in Braf-deficient mice , 1997, Nature Genetics.

[37]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[38]  G. Johnson,et al.  MEK-1 phosphorylation by MEK kinase, Raf, and mitogen-activated protein kinase: analysis of phosphopeptides and regulation of activity. , 1994, Molecular biology of the cell.

[39]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[40]  J. Haddad Oxygen-sensitive pro-inflammatory cytokines, apoptosis signaling and redox-responsive transcription factors in development and pathophysiology. , 2002, Cytokines, cellular & molecular therapy.